Alan Munoz, MD
Gynecologic Oncology · Dallas, TXNPI 1205865524
Payments from drug & device makers
Across 158 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$565
- GSK$408
- AstraZeneca$359
- Genmab U.S., Inc.$275
- AbbVie$243
- Clovis Oncology, Inc.$227
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,530100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 25 | $565 |
| GSK | 16 | $408 |
| AstraZeneca | 18 | $359 |
| Genmab U.S., Inc. | 6 | $275 |
| AbbVie | 13 | $243 |
| Clovis Oncology, Inc. | 12 | $227 |
| Eisai Inc. | 6 | $173 |
| Spectrum Pharmaceuticals Inc. | 6 | $131 |
| Heron Therapeutics, Inc. | 4 | $100 |
| Foundation Medicine, Inc. | 2 | $82 |
| Therapeuticsmd, Inc. | 5 | $69 |
| Astellas Pharma US Inc | 4 | $68 |
| Coherus Oncology, Inc. | 4 | $61 |
| Kyowa Kirin, Inc. | 3 | $58 |
| TELA Bio, Inc. | 3 | $56 |
| Daiichi Sankyo Inc. | 2 | $54 |
| Genentech USA, Inc. | 3 | $54 |
| Mylan Institutional Inc. | 4 | $52 |
| Biom'up France SAS | 1 | $45 |
| Tesaro, Inc. | 2 | $44 |
| Conmed Corporation | 1 | $44 |
| Johnson & Johnson(2 entities) | 2 | $40 |
| Novartis | 2 | $40 |
| Amgen | 2 | $39 |
| Pharmaand GmbH | 2 | $35 |
| Tempus AI, Inc | 1 | $30 |
| Caris MPI, Inc. | 1 | $28 |
| LSI Solutions Inc | 1 | $25 |
| TEI Biosciences Inc | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $21 |
| Millicent US Inc | 1 | $20 |
| Kerecis Limited | 1 | $19 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $13 |
| Immunogen, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TIVDAK$116
How this compares
$3,530 in reported general payments places this provider in the 45th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 18 | $424,481 |
| Estradiol | 16 | $822 |
| Dexamethasone | 32 | $606 |
| Clobetasol Propionate | 15 | $543 |
| Ondansetron OdtOndansetron | 32 | $264 |
| Gabapentin | 35 | $240 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 12 | $215 |
| Potassium Chloride | 25 | $212 |
| Duloxetine Hcl | 13 | $152 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $127 |
| Tramadol Hcl | 25 | $89 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $77 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $173 | $424,48118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 135 gynecologic oncology providers in Texas.
Other gynecologic oncology in Dallas
- Jayanthi LeaDallas$3.9M
- David MillerDallas$2M
- Dustin MandersDallas$171K
- Brandon SawyerDallas$131K
- Thomas HeffernanDallas$95K
- Laura DivineDallas$75K
- Jonathan OhDallas$7K
- Jessica GillenDallas$6K
- Pamela SolimanHouston$30.7M
- Noelle ClovenFort Worth$7.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.